Business Context and Reporting Period
This Form 6-K filing by PainReform Ltd. (PRF Technologies Ltd.) covers the month of January 2021, with the report dated January 4, 2021. The filing serves to disclose a corporate announcement regarding the company's clinical trial operations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an informational report regarding a specific corporate event rather than a financial statement.
Material Changes
The primary material event disclosed is the appointment of Lotus Clinical Research as the Contract Research Organization (CRO) for the Phase 3 clinical trial of the company's product candidate, PRF-110.
Guidance, Outlook, and Risks
The filing includes an explanatory note advising investors that the company may disseminate material information regarding finances, product candidates, and clinical trials via its website (https://www.painreform.com/), press releases, and webcasts. Management encourages stakeholders to monitor these channels in addition to SEC filings.
Investor Verification Checklist
- Verify the official press release titled "PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110" (Exhibit 99.1).
- Review the company website for any additional updates on the PRF-110 Phase 3 trial timeline or scope.
- Confirm the role and qualifications of Lotus Clinical Research as the new CRO.